Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil initially worked but then failed. Trinov has significantly reduced shedding and shows promising results.

RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.

The user experienced eyebrow hair loss after COVID-19 and has not seen regrowth despite using Latisse. They are seeking new treatment options but are cautious about spending money on ineffective solutions.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

The user is using finasteride, minoxidil, and ciclopirox shampoo for hair loss and is considering adding a topical anti-androgen like RU58841, Clacosterone, or KX286. They have scheduled a hair transplant and are concerned about the cost and effectiveness of future treatments.

Treatments for hair loss, specifically discussing the use of RU58841 and Pyrilutamide from Actifolic. The poster is inquiring about experiences with these products and results.

The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The focus is on setting realistic expectations for these treatments.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.